Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 3/20 | 0.31 |
| ▸ | CHUK | O15111 | 3/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124114 | 0.87 | IKBKB (0.33) | LMNAKDM4EGAAKMT2APOLB | |
| SCHEMBL8737277 | 0.86 | KDM4E (0.33) | LMNAKDM4EGAAKMT2ATP53 | |
| SCHEMBL8737256 | 0.81 | IKBKB (0.36) | LMNAKDM4EGAATP53POLB | |
| SCHEMBL4402905 | 0.74 | ADORA2A (0.39) | LMNATP53POLBIKBKBCHUK | |
| SCHEMBL12256556 | 0.74 | IKBKB (0.37) | LMNATP53POLBIKBKBCHUK | |
| SCHEMBL12258194 | 0.71 | LMNA (0.32) | LMNA | |
| SCHEMBL15082656 | 0.69 | DDB1 (0.40) | LMNAKDM4EGAAPOLBDPP4 | |
| SCHEMBL17898191 | 0.69 | ADORA1 (0.42) | KDM4EGAAADORA2AADORA1 | |
| SCHEMBL22349081 | 0.68 | ALDH1A1 (0.38) | LMNAKDM4EGAAKMT2APOLB | |
| SCHEMBL13193188 | 0.67 | CCR1 (0.37) | LMNAKDM4EGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2012-10-04 | — | — | US | disclosed |
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-05-24 | — | — | US | disclosed |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129846-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 652/4885KDM4E 2715/4885GAA 17/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 1968/4885KDM4E 3006/4885GAA 11/4885 |
| US-20120251491-A1 | FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, AADAC | LMNA 3335/4885KDM4E 3035/4885GAA 226/4885 |
| US-20110263529-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 676/4885KDM4E 2521/4885GAA 16/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | LMNA 2080/4885KDM4E 2892/4885GAA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.